Bristol-Myers Squibb Co BMY:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 4:13 PM EST

74.45UNCH (UNCH)

Volume

312,094

74.45

+1.68 (+2.31%)

Volume

9,885,875

52 week range

62.90 - 81.43

Open73.21
Day High74.47
Day Low72.61
Prev Close72.77
52 Week High81.43
52 Week High Date12/01/22
52 Week Low62.90
52 Week Low Date02/04/22

Key Stats

Market Cap158.293B
Shares Out2.13B
10 Day Average Volume8.59M
Dividend2.28
Dividend Yield3.06%
Beta0.44
YTD % Change3.47

KEY STATS

Open73.21
Day High74.47
Day Low72.61
Prev Close72.77
52 Week High81.43
52 Week High Date12/01/22
52 Week Low62.90
52 Week Low Date02/04/22
Market Cap158.293B
Shares Out2.13B
10 Day Average Volume8.59M
Dividend2.28
Dividend Yield3.06%
Beta0.44
YTD % Change3.47

RATIOS/PROFITABILITY

EPS (TTM)2.95
P/E (TTM)25.22
Fwd P/E (NTM)9.68
EBITDA (TTM)21.537B
ROE (TTM)19.11%
Revenue (TTM)46.159B
Gross Margin (TTM)78.29%
Net Margin (TTM)13.75%
Debt To Equity (MRQ)119.67%

EVENTS

Earnings Date04/27/2023(est)
Ex Div Date01/05/2023
Div Amount0.57
Split Date-
Split Factor-

Latest On Bristol-Myers Squibb Co

Pro Picks: Watch all of Thursday's big stock calls on CNBC24 Hours AgoCNBC.com
What to watch in the markets in the week aheadJanuary 27, 2023CNBC.com
Cheap quality stocks offer a smoother ride, according to Trivariate ResearchJanuary 27, 2023CNBC.com
Analysts love these stocks that are flush with cash — giving one over 75% upsideJanuary 22, 2023CNBC.com
Biden administration will select first 10 drugs for Medicare price negotiationsJanuary 11, 2023CNBC.com

Content From Our Affiliates

Morgan Stanley Reaffirms Their Sell Rating on Bristol Myers (BMY)5 Hours AgoTipRanks
Atlantic Equities Sticks to Its Buy Rating for Bristol Myers (BMY)9 Hours AgoTipRanks
Bristol Myers (BMY) Receives a Buy from BMO Capital9 Hours AgoTipRanks
Bristol Myers (BMY) Gets a Hold from Barclays9 Hours AgoTipRanks
Bank of America Securities Sticks to Their Buy Rating for Bristol Myers (BMY)10 Hours AgoTipRanks

Profile

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics....

Giovanni Caforio M.D.

Chairman of the Board, Chief Executive Officer

David Elkins

Executive Vice President, Chief Financial Officer, Member of the Leadership Team

Elizabeth Mily

Executive Vice President - Strategy and Business Development, Member of the Leadership Team

Sandra Leung

Executive Vice President, General Counsel, Member of the Leadership Team

Christopher Boerner Ph.D.

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

Address

430 E. 29Th Street, 14 Floor

New York, NY

10016

United States

https://www.bms.com/